Answers are grounded in this paper and cite their sources.
rhVEGF seems to be safe and well tolerated. rhVEGF offered no improvement beyond placebo in all measurements by day 60. By day 120, high-dose rhVEGF resulted in significant improvement in angina and favorable trends in ETT time and angina frequency.
No takes yet. Share an insight, caveat, or question.
Henry et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: